Bispecific antibodies against CEACAM5 and CD47
US11753481B2 · kind B2 · utility
0Cited by
9References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 17, 2021 |
| Grant date | Sep 12, 2023 |
| Priority date | — |
| Expiry date | Dec 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.